Tenet Healthcare Co. (NYSE:THC - Free Report) - Investment analysts at Zacks Research reduced their Q4 2024 earnings per share estimates for Tenet Healthcare in a report released on Wednesday, December 18th. Zacks Research analyst R. Department now expects that the company will earn $2.87 per share for the quarter, down from their previous estimate of $2.88. The consensus estimate for Tenet Healthcare's current full-year earnings is $11.38 per share. Zacks Research also issued estimates for Tenet Healthcare's Q2 2025 earnings at $2.66 EPS, Q4 2025 earnings at $3.20 EPS and Q1 2026 earnings at $3.45 EPS.
Tenet Healthcare (NYSE:THC - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.93 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.60. Tenet Healthcare had a net margin of 14.91% and a return on equity of 24.05%. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.05 billion. During the same period in the previous year, the firm posted $1.44 earnings per share. The business's revenue was up 1.1% compared to the same quarter last year.
A number of other equities research analysts have also commented on THC. Cantor Fitzgerald increased their price target on Tenet Healthcare from $168.00 to $177.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. UBS Group upped their price objective on shares of Tenet Healthcare from $197.00 to $217.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Barclays boosted their target price on Tenet Healthcare from $171.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, November 8th. The Goldman Sachs Group lowered Tenet Healthcare from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $196.00 to $140.00 in a report on Monday, December 16th. Finally, Raymond James downgraded Tenet Healthcare from a "strong-buy" rating to an "outperform" rating and set a $195.00 price objective for the company. in a research note on Friday, November 22nd. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $166.88.
Get Our Latest Stock Report on THC
Tenet Healthcare stock opened at $129.46 on Monday. The company has a current ratio of 1.58, a quick ratio of 1.52 and a debt-to-equity ratio of 2.35. The firm's fifty day moving average price is $149.74 and its two-hundred day moving average price is $149.14. The firm has a market capitalization of $12.31 billion, a price-to-earnings ratio of 4.15, a price-to-earnings-growth ratio of 0.61 and a beta of 2.06. Tenet Healthcare has a 1-year low of $73.21 and a 1-year high of $171.20.
In related news, EVP Lisa Y. Foo sold 4,000 shares of the business's stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $155.94, for a total transaction of $623,760.00. Following the completion of the transaction, the executive vice president now directly owns 15,566 shares in the company, valued at approximately $2,427,362.04. The trade was a 20.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.93% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in THC. Coldstream Capital Management Inc. boosted its stake in Tenet Healthcare by 2.2% during the third quarter. Coldstream Capital Management Inc. now owns 3,406 shares of the company's stock valued at $566,000 after buying an additional 74 shares during the last quarter. Optas LLC increased its position in Tenet Healthcare by 3.4% in the third quarter. Optas LLC now owns 2,821 shares of the company's stock worth $469,000 after purchasing an additional 93 shares during the last quarter. Signaturefd LLC lifted its position in Tenet Healthcare by 17.6% during the third quarter. Signaturefd LLC now owns 628 shares of the company's stock valued at $104,000 after purchasing an additional 94 shares during the last quarter. CIBC Asset Management Inc increased its holdings in shares of Tenet Healthcare by 3.4% in the 3rd quarter. CIBC Asset Management Inc now owns 2,887 shares of the company's stock worth $480,000 after buying an additional 94 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Tenet Healthcare by 20.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 560 shares of the company's stock valued at $74,000 after acquiring an additional 96 shares during the last quarter. Institutional investors own 95.44% of the company's stock.
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Tenet Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenet Healthcare wasn't on the list.
While Tenet Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.